Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Spondyloarthritis Clinic: Organizational Improvements in the Patient Journey.

Frontiers in medicine·2022
Same author

Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis.

Scientific reports·2022
Same author

Female sexual dysfunction in systemic sclerosis: The role of endothelial growth factor and endostatin.

Journal of scleroderma and related disorders·2022
Same author

Duration of clinical remission and low disease activity impacts on quality of life and its domains in psoriatic arthritis patients: results from an Italian multicentre study.

Clinical and experimental rheumatology·2021
Same author

Metabolic syndrome and adipokine levels in systemic lupus erythematosus and systemic sclerosis.

Clinical rheumatology·2021
Same author

JAK inhibitors in immune-mediated rheumatic diseases: From a molecular perspective to clinical studies.

Journal of molecular graphics & modelling·2021

Related Experiment Video

Updated: Jun 10, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Cirrhotic cardiomyopathy.

Enrico M Zardi1, Antonio Abbate, Domenico Maria Zardi

  • 1Department of Clinical Medicine, University Campus Bio-Medico, Via Alvaro del Portillo, Rome, Italy. e.zardi@unicampus.it

Journal of the American College of Cardiology
|August 7, 2010
PubMed
Summary

Cirrhotic cardiomyopathy, a heart condition in liver cirrhosis patients, presents with a blunted stress response but normal resting cardiac function. This cardiac dysfunction affects up to 50% of liver transplant candidates, increasing heart failure risks.

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

Related Experiment Videos

Last Updated: Jun 10, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

Area of Science:

  • Cardiology
  • Hepatology
  • Transplantation Medicine

Background:

  • Cirrhotic cardiomyopathy (CC) is a distinct cardiac syndrome in liver cirrhosis patients.
  • It is characterized by impaired cardiac response to stress, despite normal or hyperdynamic resting cardiac function.
  • CC affects a significant portion of liver transplant candidates and is linked to post-transplant mortality.

Purpose of the Study:

  • To critically evaluate the existing literature on cirrhotic cardiomyopathy.
  • To review the pathophysiology of CC in patients with liver cirrhosis.
  • To discuss the clinical implications of CC, particularly in the context of liver transplantation.

Main Methods:

  • Comprehensive literature review of existing studies on cirrhotic cardiomyopathy.
  • Analysis of research on the pathophysiology of cardiac dysfunction in liver cirrhosis.
  • Evaluation of clinical data regarding the impact of CC on liver transplantation outcomes.

Main Results:

  • Up to 50% of patients with liver cirrhosis undergoing liver transplantation exhibit cardiac dysfunction.
  • Overt heart failure accounts for 7% to 21% of deaths following orthotopic liver transplantation.
  • The review synthesizes current understanding of CC's mechanisms and clinical relevance.

Conclusions:

  • Cirrhotic cardiomyopathy is a significant clinical entity in liver disease.
  • Understanding CC pathophysiology is crucial for managing cirrhotic patients, especially those awaiting or undergoing liver transplantation.
  • Further research is needed to optimize management strategies and improve outcomes for patients with CC.